Results about: patients

Joan Massagué calls on society to get on board with the challenge posed by metastasis

High-ranking figures from the business and innovation sectors attended an event organised by IRB Barcelona and ESADE with the aim to highlight the importance of uniting all sectors of society against metastasis.

Cancer metastases slowly unveil their weaknesses

Advances in research into the immunological evasion, metabolism and latency of metastatic cancer cells allow the identification of potential targets to test therapies.

IRB Barcelona and the BBVA Foundation invite 20 renowned international scientists working in the field of cancer metastasis to a gathering in Barcelona.

After the scientific conference, IRB Barcelona and ESADE have organised a debate on how to translate scientific research to society.

An international consortium identifies the breast cancer patients who would benefit from a treatment to prevent metastasis

A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.

This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.

Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.